1. history of allergic disease or reactions likely to be exacerbated by any component of azd1222. 2. active infection with sars-cov-2 as confirmed locally by nucleic acid amplification test (e.g. rt-pcr). 3. known current or past laboratory-confirmed sars-cov-2 infection. 4. significant infection or other acute illness, including fever (temperature \> 37.8°c) on the day prior to or day of first dosing. 5. thrombocytopenia with platelet count ≤ 75,000 x 109/microliter based on complete blood count test at screening visit. 6. hiv-positive participants based on a positive elisa test performed at screening visit. 7. history of cerebral venous sinus thrombosis (cvst). 8. receipt of any vaccine (licensed or investigational) within 30 days prior to and after administration of azd1222.

1. history of allergic disease or reactions likely to be exacerbated by any component of azd1222. 2. active infection with sars-cov-2 as confirmed locally by nucleic acid amplification test (e.g. rt-pcr). 3. known current or past laboratory-confirmed sars-cov-2 infection. 4. significant infection or other acute illness, including fever (temperature \> 37.8°c) on the day prior to or day of first dosing. 5. thrombocytopenia with platelet count ≤ 75,000 x 109/microliter based on complete blood count test at screening visit. 6. hiv-positive participants based on a positive elisa test performed at screening visit. 7. history of cerebral venous sinus thrombosis (cvst). 8. receipt of any vaccine (licensed or investigational) within 30 days prior to and after administration of azd1222.

history of allergic disease or reactions likely to be exacerbated by any component of azd1222. active infection with sars-cov-2 as confirmed locally by nucleic acid amplification test (e.g. rt-pcr). known current or past laboratory-confirmed sars-cov-2 infection. significant infection or other acute illness, including fever (temperature > 37.8°c) on the day prior to or day of first dosing. thrombocytopenia with platelet count ≤ 75,000 x 109/microliter based on complete blood count test at screening visit. hiv-positive participants based on a positive elisa test performed at screening visit. history of cerebral venous sinus thrombosis (cvst). receipt of any vaccine (licensed or investigational) within 30 days prior to and after administration of azd1222.

history of allergic disease or reactions likely to be exacerbated by any component of azd1222. active infection with sars-cov-2 as confirmed locally by nucleic acid amplification test (e.g. rt-pcr). known current or past laboratory-confirmed sars-cov-2 infection. significant infection or other acute illness, including fever (temperature > 37.8°c) on the day prior to or day of first dosing. thrombocytopenia with platelet count ≤ 75,000 x 109/microliter based on complete blood count test at screening visit. hiv-positive participants based on a positive elisa test performed at screening visit. history of cerebral venous sinus thrombosis (cvst). receipt of any vaccine (licensed or investigational) within 30 days prior to and after administration of azd1222.

history of allergic disease or reactions likely to be exacerbated by any component of azd1222. active infection with sars-cov-2 as confirmed locally by rt-pcr. known past laboratory-confirmed sars-cov-2 infection. significant infection or other acute illness, including fever (temperature > 37.8°c) on the day prior to or day of first dosing. thrombocytopenia with platelet count ≤ 75,000 x 109/microliter based on complete blood count test at screening visit. hiv-positive participants based on a positive elisa test performed at screening visit. history of cerebral venous sinus thrombosis (cvst). receipt of any vaccine (licensed or investigational) within 30 days prior to and after administration of azd1222.

history of allergic disease or reactions likely to be exacerbated by any component of azd1222. active infection with sars-cov-2 as confirmed locally by rt-pcr. known past laboratory-confirmed sars-cov-2 infection. significant infection or other acute illness, including fever (temperature > 37.8°c) on the day prior to or day of first dosing. thrombocytopenia with platelet count ≤ 75,000 x 109/microliter based on complete blood count test at screening visit. hiv-positive participants based on a positive elisa test performed at screening visit. history of cerebral venous sinus thrombosis (cvst). receipt of any vaccine (licensed or investigational) within 30 days prior to and after administration of azd1222.

1. history of allergic disease or reactions likely to be exacerbated by any component of azd1222. 2. active infection with sars-cov-2 as confirmed locally by rt-pcr. 3. known past laboratory-confirmed sars-cov-2 infection. 4. significant infection or other acute illness, including fever (temperature > 37.8°c) on the day prior to or day of first dosing. 5. thrombocytopenia with platelet count ≤ 75,000 x 109/microliter based on complete blood count test at screening visit. 6. hiv-positive participants based on a positive elisa test performed at screening visit. 7. history of cerebral venous sinus thrombosis (cvst). 8. receipt of any vaccine (licensed or investigational) within 30 days prior to and after administration of azd1222.

1. history of allergic disease or reactions likely to be exacerbated by any component of azd1222. 2. active infection with sars-cov-2 as confirmed locally by rt-pcr. 3. known past laboratory-confirmed sars-cov-2 infection. 4. significant infection or other acute illness, including fever (temperature > 37.8°c) on the day prior to or day of first dosing. 5. thrombocytopenia with platelet count ≤ 75,000 x 109/microliter based on complete blood count test at screening visit. 6. hiv-positive participants based on a positive elisa test performed at screening visit. 7. history of cerebral venous sinus thrombosis (cvst). 8. receipt of any vaccine (licensed or investigational) within 30 days prior to and after administration of azd1222.